Last 12 months
Inside the activity.
5 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 5 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2025 Filed Jan 7, 2025 20:49 UTC |
Buten MatthewChief Financial Officer
|
Tax withholdingCommon Shares | 2,561 | $38.64 | $98,957.04 |
DisclosureSEC source: 0001935979-25-000003 · wk-form4_1736300950.xml · nonDerivative · entry 2 Buten Matthew · CIK 0001898799 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,452 F2 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. F1 · balance_after: This balance includes 305 shares that were acquired through the Biohaven Employee Share Purchase Plan (the "ESPP") on May 31, 2023, 1,336 shares acquired through the ESPP on November 30, 2023, and 742 shares acquired through the ESPP on May 31, 2024. Read SEC document |
| January 05, 2025 Filed Jan 7, 2025 20:49 UTC |
Buten MatthewChief Financial Officer
|
Exercise / conversionCommon Shares | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000003 · wk-form4_1736300950.xml · nonDerivative · entry 1 Buten Matthew · CIK 0001898799 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance includes 305 shares that were acquired through the Biohaven Employee Share Purchase Plan (the "ESPP") on May 31, 2023, 1,336 shares acquired through the ESPP on November 30, 2023, and 742 shares acquired through the ESPP on May 31, 2024. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:51 UTC |
Car BruceChief Scientific Officer
|
Exercise / conversionRestricted Share Unit Award · Derivative | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000006 · wk-form4_1736301080.xml · derivative · entry 6 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Shares · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted 19,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:51 UTC |
Car BruceChief Scientific Officer
|
GrantRestricted Share Unit Award · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000006 · wk-form4_1736301080.xml · derivative · entry 5 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Shares · 19,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted 19,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:51 UTC |
Car BruceChief Scientific Officer
|
GrantStock Options (Right to buy) · Derivative | 112,000 | $0.00 Strike: $38.64 | $0.00 |
DisclosureSEC source: 0001935979-25-000006 · wk-form4_1736301080.xml · derivative · entry 4 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Shares · 112,000 shares Expires 2035-01-05 F2 · derivative.exercise_date: The shares underlying this option vest in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:51 UTC |
Car BruceChief Scientific Officer
|
Tax withholdingCommon Shares | 2,331 | $38.64 | $90,069.84 |
DisclosureSEC source: 0001935979-25-000006 · wk-form4_1736301080.xml · nonDerivative · entry 2 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,802 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:51 UTC |
Car BruceChief Scientific Officer
|
Exercise / conversionCommon Shares | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000006 · wk-form4_1736301080.xml · nonDerivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:50 UTC |
Clark George C.VP, Chief Accounting Officer
|
Exercise / conversionRestricted Share Unit Award · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000004 · wk-form4_1736300995.xml · derivative · entry 6 Clark George C. · CIK 0001878290 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Shares · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F5 · derivative.exercise_date: The reporting person was granted 10,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F6 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:50 UTC |
Clark George C.VP, Chief Accounting Officer
|
GrantRestricted Share Unit Award · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000004 · wk-form4_1736300995.xml · derivative · entry 5 Clark George C. · CIK 0001878290 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F5 · derivative.exercise_date: The reporting person was granted 10,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F6 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:50 UTC |
Clark George C.VP, Chief Accounting Officer
|
GrantStock Options (Right to buy) · Derivative | 30,000 | $0.00 Strike: $38.64 | $0.00 |
DisclosureSEC source: 0001935979-25-000004 · wk-form4_1736300995.xml · derivative · entry 4 Clark George C. · CIK 0001878290 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2035-01-05 F3 · derivative.exercise_date: The shares underlying this option vest in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:50 UTC |
Clark George C.VP, Chief Accounting Officer
|
Tax withholdingCommon Shares | 1,117 | $38.64 | $43,160.88 |
DisclosureSEC source: 0001935979-25-000004 · wk-form4_1736300995.xml · nonDerivative · entry 2 Clark George C. · CIK 0001878290 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,051 F2 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. F1 · balance_after: This balance includes 305 shares that were acquired through the Biohaven Employee Share Purchase Plan (the "ESPP") on May 31, 2023, 1,336 shares acquired through the ESPP on November 30, 2023, and 742 shares acquired through the ESPP on May 31, 2024. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:50 UTC |
Clark George C.VP, Chief Accounting Officer
|
Exercise / conversionCommon Shares | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000004 · wk-form4_1736300995.xml · nonDerivative · entry 1 Clark George C. · CIK 0001878290 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance includes 305 shares that were acquired through the Biohaven Employee Share Purchase Plan (the "ESPP") on May 31, 2023, 1,336 shares acquired through the ESPP on November 30, 2023, and 742 shares acquired through the ESPP on May 31, 2024. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:50 UTC |
Gentile KimberlySVP, Clinical Operations
|
Exercise / conversionRestricted Share Unit Award · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000005 · wk-form4_1736301044.xml · derivative · entry 5 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Shares · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted 15,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:50 UTC |
Gentile KimberlySVP, Clinical Operations
|
GrantRestricted Share Unit Award · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000005 · wk-form4_1736301044.xml · derivative · entry 4 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F3 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted 15,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:50 UTC |
Gentile KimberlySVP, Clinical Operations
|
GrantStock Options (Right to buy) · Derivative | 91,000 | $0.00 Strike: $38.64 | $0.00 |
DisclosureSEC source: 0001935979-25-000005 · wk-form4_1736301044.xml · derivative · entry 3 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Shares · 91,000 shares Expires 2035-01-05 F2 · derivative.exercise_date: The shares underlying this option vest in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:50 UTC |
Gentile KimberlySVP, Clinical Operations
|
Tax withholdingCommon Shares | 1,956 | $38.64 | $75,579.84 |
DisclosureSEC source: 0001935979-25-000005 · wk-form4_1736301044.xml · nonDerivative · entry 2 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,763 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:50 UTC |
Gentile KimberlySVP, Clinical Operations
|
Exercise / conversionCommon Shares | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000005 · wk-form4_1736301044.xml · nonDerivative · entry 1 Gentile Kimberly · CIK 0001704186 · SVP, Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:48 UTC |
Coric VladDirector · Chief Executive Officer
|
Exercise / conversionRestricted Share Unit Award · Derivative | 14,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000002 · wk-form4_1736300913.xml · derivative · entry 8 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,750 Underlying: Common Shares · 14,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F5 · derivative.exercise_date: The reporting person was granted 57,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F6 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:48 UTC |
Coric VladDirector · Chief Executive Officer
|
GrantRestricted Share Unit Award · Derivative | 57,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000002 · wk-form4_1736300913.xml · derivative · entry 7 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Shares · 57,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F4 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer. F5 · derivative.exercise_date: The reporting person was granted 57,000 restricted share units on January 5, 2025, vesting in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the reporting person's continued service with the Issuer at each vesting date. F6 · derivative.expiration_date: Not applicable. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:48 UTC |
Coric VladDirector · Chief Executive Officer
|
GrantStock Options (Right to buy) · Derivative | 343,000 | $0.00 Strike: $38.64 | $0.00 |
DisclosureSEC source: 0001935979-25-000002 · wk-form4_1736300913.xml · derivative · entry 6 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,000 Underlying: Common Shares · 343,000 shares Expires 2035-01-05 F3 · derivative.exercise_date: The shares underlying this option vest in four equal installments on January 5, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:48 UTC |
Coric VladDirector · Chief Executive Officer
|
Tax withholdingCommon Shares | 6,805 | $38.64 | $262,945.20 |
DisclosureSEC source: 0001935979-25-000002 · wk-form4_1736300913.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,796,604 F1 · shares: No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units. Read SEC document |
| January 05, 2025 Filed Jan 8, 2025 01:48 UTC |
Coric VladDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 14,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001935979-25-000002 · wk-form4_1736300913.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,803,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2024 Filed Dec 31, 2024 12:00 UTC |
CHILDS JOHN WDirector
|
PurchaseCommon Shares | 29,000 | $35.94 | $1,042,393.40 |
DisclosureSEC source: 0001935979-24-000088 · wk-form4_1735646406.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,368,741 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.57 - $36.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 11:01 UTC |
CHILDS JOHN WDirector
|
PurchaseCommon Shares | 21,052 | $47.50 | $999,970.00 |
DisclosureSEC source: 0001935979-24-000078 · wk-form4_1727953276.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2007 Charitable Remainder Trust Disclosed balance after: 21,052 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 11:00 UTC |
Coric VladDirector · Chief Executive Officer
|
PurchaseCommon Shares | 21,052 | $47.50 | $999,970.00 |
DisclosureSEC source: 0001935979-24-000077 · wk-form4_1727953231.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By: The Vlad Coric Family Trust Disclosed balance after: 861,942 F1 · shares: Represents common shares acquired in an underwritten public offering. F2 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 24, 2024 Filed Sep 25, 2024 11:30 UTC |
Bailey GregoryDirector
|
PurchaseCommon Shares | 5,000 | $44.19 | $220,966.00 |
DisclosureSEC source: 0001935979-24-000075 · wk-form4_1727263813.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,620,071 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.13 - $44.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| July 18, 2024 Filed Jul 19, 2024 12:56 UTC |
CHILDS JOHN WDirector
|
PurchaseCommon Shares | 28,400 | $35.67 | $1,012,982.56 |
DisclosureSEC source: 0001562180-24-005805 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,339,741 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.485 - $35.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 11:30 UTC |
Car BruceChief Scientific Officer
|
PurchaseCommon Shares | 30,000 | $33.58 | $1,007,490.00 |
DisclosureSEC source: 0001562180-24-005174 · primarydocument.xml · nonDerivative · entry 1 Car Bruce · CIK 0001798876 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By IRA Disclosed balance after: 30,000 Read SEC document |
| May 30, 2024 Filed May 31, 2024 13:04 UTC |
CHILDS JOHN WDirector
|
PurchaseCommon Shares | 28,000 | $35.58 | $996,240.00 |
DisclosureSEC source: 0001562180-24-004529 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,311,341 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.29 - $35.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 13, 2024 Filed May 14, 2024 11:30 UTC |
CHILDS JOHN WDirector
|
PurchaseCommon Shares | 28,500 | $35.17 | $1,002,470.40 |
DisclosureSEC source: 0001562180-24-004011 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,283,341 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.00 - $35.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 13, 2024 Filed May 15, 2024 11:31 UTC |
Bailey GregoryDirector
|
PurchaseCommon Shares | 15,000 | $34.19 | $512,877.00 |
DisclosureSEC source: 0001562180-24-004045 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,615,071 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.11 - $34.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:32 UTC |
CHILDS JOHN WDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001562180-24-003750 · primarydocument.xml · derivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Shares · 16,592 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:34 UTC |
Mehta KishanDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001562180-24-003755 · primarydocument.xml · derivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Shares · 16,592 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:33 UTC |
Heffernan Michael ThomasDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001562180-24-003754 · primarydocument.xml · derivative · entry 1 Heffernan Michael Thomas · CIK 0001448914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Shares · 16,592 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:33 UTC |
GREGORY JULIA PDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001562180-24-003753 · primarydocument.xml · derivative · entry 1 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Shares · 16,592 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:33 UTC |
HUGIN ROBERT JDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001562180-24-003752 · primarydocument.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Shares · 16,592 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:33 UTC |
Antonijevic IrinaDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001562180-24-003751 · primarydocument.xml · derivative · entry 1 Antonijevic Irina · CIK 0001926476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Shares · 16,592 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:32 UTC |
Bailey GregoryDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001562180-24-003749 · primarydocument.xml · derivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Shares · 16,592 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| April 24, 2024 Filed Apr 25, 2024 11:32 UTC |
Bailey GregoryDirector
|
PurchaseCommon Shares | 25,503 | $39.18 | $999,169.29 |
DisclosureSEC source: 0001562180-24-003521 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,600,071 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.13 - $39.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 11:54 UTC |
CHILDS JOHN WDirector
|
PurchaseCommon Shares | 73,170 | $41.00 | $2,999,970.00 |
DisclosureSEC source: 0001562180-24-003494 · primarydocument.xml · nonDerivative · entry 3 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,254,841 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 11:54 UTC |
CHILDS JOHN WDirector
|
PurchaseCommon Shares | 97,560 | $41.00 | $3,999,960.00 |
DisclosureSEC source: 0001562180-24-003494 · primarydocument.xml · nonDerivative · entry 2 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2021 B-H Charitable Remainder Trust Disclosed balance after: 4,096,512 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 11:54 UTC |
CHILDS JOHN WDirector
|
PurchaseCommon Shares | 24,391 | $41.00 | $1,000,031.00 |
DisclosureSEC source: 0001562180-24-003494 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 1994 Charitable Remainder Trust Disclosed balance after: 24,391 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 11:54 UTC |
Bailey GregoryDirector
|
PurchaseCommon Shares | 48,780 | $41.00 | $1,999,980.00 |
DisclosureSEC source: 0001562180-24-003495 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,574,568 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 11:54 UTC |
Coric VladDirector · Chief Executive Officer
|
PurchaseCommon Shares | 121,951 | $41.00 | $4,999,991.00 |
DisclosureSEC source: 0001562180-24-003493 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,788,417 F1 · shares: Represents common shares acquired in an underwritten public offering. Read SEC document |
| April 22, 2024 Filed Mar 5, 2025 11:59 UTC Amendment |
CHILDS JOHN WDirector
|
PurchaseCommon Shares | 73,170 | $41.00 | $2,999,970.00 |
DisclosureSEC source: 0001935979-25-000017 · wk-form4a_1741175981.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By 2013 Charitable Remainder Trust Disclosed balance after: 73,170 F1 · shares: Represents common shares acquired in an underwritten public offering. F2 · shares: This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on April 23, 2024 (the "Original Form 4"). The Original Form 4 inadvertently misstated that 73,170 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust. However, as reflected in this amendment, 73,170 Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust, and no Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust. F2 · balance_after: This amendment is being filed to correct the nature of the indirect ownership reported in the Form 4 filed on April 23, 2024 (the "Original Form 4"). The Original Form 4 inadvertently misstated that 73,170 Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust. However, as reflected in this amendment, 73,170 Common Shares were indirectly acquired by the Reporting Person through the 2013 Charitable Remainder Trust, and no Common Shares were indirectly acquired by the Reporting Person through the John W Childs 2013 Revocable Trust. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:21 UTC |
CHILDS JOHN WDirector
|
GrantCommon Shares | 2,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-003337 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,181,671 F1 · kind: Pursuant to a merger transaction, consummated on January 8, 2024, 48,505 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 2,091 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to a merger transaction, consummated on January 8, 2024, 48,505 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 2,091 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:21 UTC |
Coric VladDirector · Chief Executive Officer
|
GrantCommon Shares | 231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-003336 · primarydocument.xml · nonDerivative · entry 3 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By: The Vladimir Coric Marital Trust Disclosed balance after: 407,213 F1 · kind: Pursuant to merger transaction, consummated on January 8, 2024, 16,168 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 694 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to merger transaction, consummated on January 8, 2024, 16,168 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 694 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F2 · ownership.nature: These common shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:21 UTC |
Coric VladDirector · Chief Executive Officer
|
GrantCommon Shares | 231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-003336 · primarydocument.xml · nonDerivative · entry 2 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By: The Vlad Coric Family Trust Disclosed balance after: 840,890 F1 · kind: Pursuant to merger transaction, consummated on January 8, 2024, 16,168 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 694 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to merger transaction, consummated on January 8, 2024, 16,168 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 694 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F2 · ownership.nature: These common shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:21 UTC |
Coric VladDirector · Chief Executive Officer
|
GrantCommon Shares | 232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-003336 · primarydocument.xml · nonDerivative · entry 1 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,666,466 F1 · kind: Pursuant to merger transaction, consummated on January 8, 2024, 16,168 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 694 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to merger transaction, consummated on January 8, 2024, 16,168 common shares of the Issuer were received by the Reporting Person in exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. The issuer subsequently determined that an error was made in the calculation of the number of common shares issued and on April 5, 2024, an additional 694 common shares of the Issuer were received by the Reporting Person related to the exchange for shares of common stock of the acquired company held by the Reporting Person in a transaction approved by the Board of the Issuer pursuant to Rule 16b-3. Read SEC document |
| March 08, 2024 Filed Mar 8, 2024 23:35 UTC |
CHILDS JOHN WDirector
|
GrantCommon Shares | 19,412 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-002510 · primarydocument.xml · nonDerivative · entry 1 CHILDS JOHN W · CIK 0001027035 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By John W Childs 2013 Revocable Trust Disclosed balance after: 2,179,580 F1 · kind: Pursuant to an agreement and plan of merger, dated as of January 7, 2024, common shares of the Issuer were issued to the Reporting Person on March 8, 2024. The acquisition of the acquired company pursuant to the agreement and plan of merger and the issuance of common shares of the Issuer to the Reporting Person in connection therewith were approved by the Board of the Issuer pursuant to Rule 16b-3. F1 · price: Pursuant to an agreement and plan of merger, dated as of January 7, 2024, common shares of the Issuer were issued to the Reporting Person on March 8, 2024. The acquisition of the acquired company pursuant to the agreement and plan of merger and the issuance of common shares of the Issuer to the Reporting Person in connection therewith were approved by the Board of the Issuer pursuant to Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.